While the translational relevance of EGFR-directed therapy may be greater in tumors such as non-small cell lung cancer, colorectal cancer, glioblastoma, or breast cancer, the findings from our model provide insights into EGFR-targeted immune strategies that may be extended to EGFR-expressing cancers. The gene discussed is EGFR; the disease is glioblastoma.